Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 12, 2014, Pages

  Kew, Kayleigh M ^a   Allison, Debbie E ^b   Evans, David J W ^c   Boyter, Anne C ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c ROYAL LANCASTER INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; CORTICOSTEROID; GLYCOPYRRONIUM; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; RESPIMAT; TIOTROPIUM BROMIDE;

ADD ON THERAPY; ADVERSE EVENT; ARTICLE; ASTHMA; CLINICAL OUTCOME; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HOSPITALIZATION; HUMAN; LUNG FUNCTION; METHODOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 85041705884     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011437     Document Type: Article

References (24)

1. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD002738.pub2]
2. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4]
3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. American Journal of Respiratory and Critical Care Medicine 170;8:836-44.
4. Joint Formulary Committee. British National Formulary (online). http://www.medicinescomplete.com. London: BMJ Group and Pharmaceutical Press, accessed 27 August 2014.
5. Brozek J, Oxman A, Schünemann H. GradePro Version 3.2 for Windows. McMaster University, 2014, 2008.
6. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD003137.pub5]
7. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2]
8. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2]
9. Ducharme FM, Ni Choinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2]
10. License extension 19th September 2014: Spiriva Respimat 2.5 micrograms solution for inhalation. https://www.medicines.org.uk/emc/history/20134 (accessed 24 October 2014).
11. Global Initiative for Asthma. Global Strategy For Asthma Management And Prevention. http://www.ginasthma.org/(accessed 22nd August 2014).
12. International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. http://theunion.org/what-we-do/publications/technical/global-asthma-report (accessed 28th August 2014).
13. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respiratory Research 2006;7(1):73.
14. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
15. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3]
16. Lipworth BJ. Emerging role of long acting muscarinic antagonists for asthma. British Journal of Clinical Pharmacology 2014;77(1):55-62.
17. Moulton BC, Fryer AD. Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. British Journal of Clinical Pharmacology 2011;163(1):44-52.
18. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD010509.pub2]
19. National Institute for Health and Care Excellence. NICE advice [KTT5]High-dose inhaled corticosteroids in asthma. http://www.nice.org.uk/Advice/ktt5 (accessed 29th August 2014).
20. Royal College of Physicians. Why asthma still kills: the national review of asthma deaths. https://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf (accessed 28th August 2014).
21. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
22. Tee A, Koh MS, Gibson PG, Lasserson TJ, Wilson A, Irving LB. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001281.pub2]
23. Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG, Sturkenboom MC. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patient with COPD. European Respiratory Journal 42;3:606-15.
24. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium Respimat Inhaler and the risk of death in COPD. New England Journal of Medicine 2013;369:1491-1501.